WO1997040165B1 - Novel human cytomegalovirus dna constructs and uses therefor - Google Patents
Novel human cytomegalovirus dna constructs and uses thereforInfo
- Publication number
- WO1997040165B1 WO1997040165B1 PCT/US1997/006866 US9706866W WO9740165B1 WO 1997040165 B1 WO1997040165 B1 WO 1997040165B1 US 9706866 W US9706866 W US 9706866W WO 9740165 B1 WO9740165 B1 WO 9740165B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogenic composition
- pδrc
- group
- hcmv
- human cytomegalovirus
- Prior art date
Links
- 229920003013 deoxyribonucleic acid Polymers 0.000 title claims abstract 12
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims 12
- 230000028993 immune response Effects 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 230000002163 immunogen Effects 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 239000000969 carrier Substances 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000002845 Virion Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003362 replicative Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229960005486 vaccines Drugs 0.000 abstract 1
Abstract
Novel DNA molecules for in vitro and in vivo expression of HCMV gB, gB transmembrane-deleted derivatives, pp65, pp150, and IE-exon-4 proteins are described. Preferably, the molecules are plasmids. Also described are methods of using these DNA molecules to induce immune responses to HCMV, and the use of a plasmid of the invention to prime immune responses to HCMV vaccines.
Claims
AMENDED CLAIMS
[received by the International Bureau on 25 November 1997 (25.11.97); original claims 13-28 replaced by new claims 13-32; remaining claims unchanged (4 pages)]
13. A pCBgBΔtm plasmid, said plasmid comprising the human cytomegalovirus (HCMV) gB gene containing a deletion in the transmembrane domain.
14. An immunogenic composition comprising a carrier and a DNA molecule according to any of claims 1-5.
15. The immunogenic composition according to claim 14 wherein the DNA molecule is selected from the group consisting of:
(a) pΔRC-gB;
(b) pTet-gB;
(c) pΔRC-pp65;
(d) pΔRC-gE ;
(e) pΔRC-ppl50;
(f) pCBgB;
(g) pCBgBΔtm; and (h) pΔRC-exon-4.
16. The immunogenic composition according to claim 14 or 15 comprising two or more DNA molecules.
17. The immunogenic composition according to claim 15 comprising a first DNA molecule which comprises a sequence encoding the gB antigen or a gB derivative, and a second DNA molecule which comprises a sequence encoding the pp65 antigen.
18. The immunogenic composition according to any of claims 13 to 17 wherein the carrier is selected from the group consisting of saline and isotonic water.
44
19. A method of inducing human cytomegalovirus-specific (HCMV) immune responses in an animal, comprising the step of administering to said animal an effective amount of a first immunogenic composition according to any of claims 14 to 18.
20. The method according to claim 19 wherein the composition comprises pTet-gB and pΔRC-pp65.
21. The method according to claim 19 further comprising the step of administering a second immunogenic composition to said animal, said second immunogenic composition comprising a plasmid selected from the group consisting of:
(a) pΔRC-gB;
(b) pTet-gB;
(c) pΔRC-pρ65;
(d) pΔRC-gE ;
(e) pΔRC-ppl 50;
(f) pCBgB;
(g) pCBgBΔtm; and (h) pΔRC-IE-Exon-4.
22. The method according to claim 19, wherein said second immunogenic composition is administered between about 2 to about 15 weeks following administration of said first immunogenic composition.
23. The use of a DNA molecule according to any of claims 1 to 5 or a plasmid according to any of claims 6 to 13 in the preparation of a medicament to treat a cytomegalovirus infection.
45
24. A method of priming immune responses to a selected human cytomegalovirus immunogenic composition, comprising the steps of: administering a first immunogenic composition according to any of claims 14 to 18 and administering the selected human cytomegalovirus immunogenic composition.
25. The method according to claim 24 wherein the first immunogenic composition is administered between about 4 and 15 weeks prior to administration of the selected immunogenic composition.
26. The method according to claim 24 or claim 25 wherein the first immunogenic composition comprises pTet-gB.
27. The method according to claim 26, wherein pTet-gB is administered in an amount between about 50 μg to about 160 μg.
28. The method according to claim 24, wherein the selected immunogenic composition comprises an immunogen selected from the group consisting of a recombinant virus comprising an HCMV immunogen, an HCMV protein, and HCMV virions.
29. The method according to claim 28 wherein the HCMV protein is gB.
30. The method according to claim 28 wherein the recombinant virus is selected from the group consisting of Ad5.gb and Ad5-lE-exon-4.
46
31. A DNA molecule which is non-replicating in mammals and comprises a sequence encoding a human cytomegalovirus antigen selected from the group consisting of:
(a) pp65; (b) pP150;
(c) immediate-early exon-4;
(d) gB and an antigen of (a) to (c);
(e) a gB derivative lacking at least the transmembrane domain and an antigen of (a) to (c); and
(f) a combination of antigens (a) to (c).
32. An immunogenic composition comprising a carrier and at least two DNA molecules, wherein said DNA molecules are selected from the group consisting of:
(a) gB;
(b) a gB derivative lacking at least the transmembrane domain;
(c) pp65; (d) ρpl50; and
(e) immediate-early exon-4.
STATEMENT UNDER ARTICLE 19
Following entry of the attached replacement pages, claims 1 - 32 are pending.
The claims have been amended to recite two plasmid constructs disclosed throughout the application, but not previously claimed. See, new claims 12 and 13, amended claims 15 and 21. Particularly, pCBgB and pCBgBΔtm are supported in Example 14, page 34, line 1 through page 37, line 10 of the specification as filed. No new matter is added by this amendment. Inclusion of these two claims requires addition of two additional inventors, as requested in the attached letter.
In addition, two new independent claims have been added, which are supported by original claims 1 and 12, but are of narrower scope. These claims are believed to overcome the prior art cited in the International Search Report.
48
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU28098/97A AU2809897A (en) | 1996-04-23 | 1997-04-22 | Novel human cytomegalovirus dna constructs and uses therefor |
| US09/171,699 US6448389B1 (en) | 1996-04-23 | 1997-04-22 | Human cytomegalovirus DNA constructs and uses therefor |
| EP97922429A EP0914441A2 (en) | 1996-04-23 | 1997-04-22 | Novel human cytomegalovirus dna constructs and uses therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1571796P | 1996-04-23 | 1996-04-23 | |
| US60/015,717 | 1996-04-23 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/171,699 A-371-Of-International US6448389B1 (en) | 1996-04-23 | 1997-04-22 | Human cytomegalovirus DNA constructs and uses therefor |
| US10/223,538 Division US20030120060A1 (en) | 1996-04-23 | 2002-08-19 | Human cytomegalovirus DNA constructs and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1997040165A1 WO1997040165A1 (en) | 1997-10-30 |
| WO1997040165B1 true WO1997040165B1 (en) | 1998-01-08 |
| WO1997040165A9 WO1997040165A9 (en) | 1998-02-12 |
Family
ID=21773167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/006866 WO1997040165A1 (en) | 1996-04-23 | 1997-04-22 | Novel human cytomegalovirus dna constructs and uses therefor |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US6448389B1 (en) |
| EP (1) | EP0914441A2 (en) |
| AU (1) | AU2809897A (en) |
| WO (1) | WO1997040165A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
| EP0964686A4 (en) | 1996-08-14 | 2000-10-18 | Wistar Inst | Methods and compositions for preventing or retarding the development of atherosclerotic lesions |
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| WO2000062817A2 (en) * | 1999-04-15 | 2000-10-26 | Board Of Regents, The University Of Texas System | Inducible vaccines |
| EP1612217A3 (en) * | 2000-03-27 | 2006-01-18 | City of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| CA2395781C (en) * | 2000-07-13 | 2010-04-13 | The Johns Hopkins University School Of Medicine | Detection and treatment of polycystic kidney disease |
| CA2421118A1 (en) * | 2000-09-09 | 2002-03-14 | Basf Plant Science Gmbh | Modified tet-inducible system for regulation of gene expression in plants |
| AU2002214624A1 (en) | 2000-10-20 | 2002-05-06 | City Of Hope | Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
| DE60233061D1 (en) * | 2001-09-06 | 2009-09-03 | Alphavax Inc | ALPHAVIRUS REPLICON VECTOR SYSTEMS |
| DE60333035D1 (en) * | 2002-12-23 | 2010-07-29 | Vical Inc | VACCINES AGAINST INFECTIONS WITH THE HUMAN CYTOMEGALIVIRUS BASED ON CODON-OPTIMIZED POLYNUCLEOTIDES |
| WO2004074439A2 (en) * | 2003-02-14 | 2004-09-02 | Biogen Idec Ma Inc. | An expression cassette and vector for transient or stable expression of exogenous molecules |
| US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
| KR101454842B1 (en) * | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
| AU2004257214B2 (en) * | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| WO2008156829A2 (en) * | 2007-06-21 | 2008-12-24 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| EP3156069B8 (en) | 2008-06-20 | 2020-10-21 | Duke University | Compositions, methods, and kits for eliciting an immune response |
| US8812387B1 (en) | 2013-03-14 | 2014-08-19 | Csidentity Corporation | System and method for identifying related credit inquiries |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2014362234B2 (en) | 2013-12-11 | 2019-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
| RU2616245C2 (en) * | 2015-12-29 | 2017-04-13 | Сейфаддин Гашим Оглы Марданлы | Composition for prevention of diseases caused by cmv infection |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| JP6980780B2 (en) | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | Human cytomegalovirus vaccine |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (en) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | Human cytomegalovirus gb polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959466A (en) | 1974-04-15 | 1976-05-25 | The Wistar Institute | Highly attenuated cytomegalovirus vaccine and production thereof |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US4689225A (en) | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
| CA1335429C (en) | 1986-03-07 | 1995-05-02 | Geoffrey L. Smith | Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor |
| DE3619720A1 (en) | 1986-06-12 | 1987-12-17 | Behringwerke Ag | MAIN GLYCOPROTEIN OF THE HUMAN CYTOMEGALOVIRUS, ITS PRODUCTION AND USE |
| ATE82985T1 (en) | 1986-06-12 | 1992-12-15 | Behringwerke Ag | STRUCTURAL PHOSPHOPROTEIN (PP 150) OF HUMAN CYTOMEGALOVIRUS, ITS PRODUCTION AND USE. |
| DE3619902A1 (en) | 1986-06-13 | 1988-03-03 | Biotechnolog Forschung Gmbh | CMV DNA STRUCTURES, EXPRESSION VECTOR DAFUER, CMV PROTEIN STRUCTURES AND THEIR USE |
| ZA878031B (en) | 1986-11-04 | 1988-04-28 | Scripps Clinic And Research Foundation | Nucleic acid probes for the detection of latent human cytomegalovirus in blood products |
| US5153311A (en) | 1986-11-24 | 1992-10-06 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus gCII |
| US5124440A (en) | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
| EP0277773A1 (en) | 1987-01-30 | 1988-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Hybrid cytomegalovirus (CMV) and vaccine |
| AU641121B2 (en) | 1988-01-29 | 1993-09-16 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| EP0429470A1 (en) | 1988-07-01 | 1991-06-05 | The Children's Hospital, Incorporated | Antibody recognition of fragments from cytomegalovirus |
| WO1990006771A1 (en) | 1988-12-12 | 1990-06-28 | The Children's Hospital, Incorporated | Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| DK0389286T3 (en) | 1989-03-24 | 1996-11-18 | Wistar Inst | Recombinant cytomegalovirus vaccine |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| WO1991002004A1 (en) | 1989-08-07 | 1991-02-21 | Children's Biomedical Research Center | IMMUNOGENIC GLYCOPROTEINS OF HUMAN CYTOMEGALOVIRUS gCII |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| GB9014652D0 (en) | 1990-07-02 | 1990-08-22 | Wellcome Found | Antigen |
| EP0541721A4 (en) | 1990-08-02 | 1993-12-29 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
| WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| WO1994023744A1 (en) | 1993-04-16 | 1994-10-27 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| IT1266740B1 (en) | 1994-07-01 | 1997-01-14 | Maria Paola Landini | RECOMBINANT PROTEIN MATERIAL BINDING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS, DIAGNOSTIC REAGENTS DERIVED FROM THIS |
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
-
1997
- 1997-04-22 AU AU28098/97A patent/AU2809897A/en not_active Abandoned
- 1997-04-22 EP EP97922429A patent/EP0914441A2/en not_active Withdrawn
- 1997-04-22 US US09/171,699 patent/US6448389B1/en not_active Expired - Lifetime
- 1997-04-22 WO PCT/US1997/006866 patent/WO1997040165A1/en not_active Application Discontinuation
-
2002
- 2002-08-19 US US10/223,538 patent/US20030120060A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997040165B1 (en) | Novel human cytomegalovirus dna constructs and uses therefor | |
| Prehaud et al. | Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors | |
| EP0139417B1 (en) | Vaccines based on membrane bound proteins and process for making them | |
| Yoo et al. | The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells | |
| CA2228221A1 (en) | Papillomavirus polyprotein constructs | |
| Konishi et al. | A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens | |
| CA2054069A1 (en) | Expression system | |
| JP2005333990A (en) | Gp350/220 non-splicing variant | |
| Sarkar et al. | Polypeptides of the mouse mammary tumor virus: II. Identification of two major glycoproteins with the viral structure | |
| EP0538341B1 (en) | Ehv-4 glycoprotein vaccine | |
| CA2275340A1 (en) | Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine | |
| EP0117657A1 (en) | Rabies immunogenic polypeptides and vaccine using them, DNA sequences, expression vectors, recombinant cells, and cultures therefor, and processes for their production | |
| Meindl et al. | The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component | |
| ALLEN et al. | Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity | |
| EP0913157B1 (en) | A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method | |
| JP2852395B2 (en) | Feline leukemia virus vaccine | |
| Frenchick et al. | Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles | |
| WO1997003187A3 (en) | Marek's disease virus genes and their use in vaccines for protection against marek's disease | |
| EP0471457A2 (en) | Herpesvirus-based viral vector which expresses a foot & mouth disease virus epitope | |
| Harty et al. | Characterization of the myristylated polypeptide encoded by the UL1 gene that is conserved in the genome of defective interfering particles of equine herpesvirus 1 | |
| KR100768051B1 (en) | A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide | |
| JPH06220099A (en) | Soluble ldl receptor | |
| Osterrieder et al. | Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity | |
| Perez-Hernandez et al. | Expression and characterization of the gD protein of HSV-2 fused to the tetramerization domain of the transcription factor p53 | |
| JP2759035B2 (en) | Herpes simplex virus infection protection vaccine |